Preclinical evaluation of a paclitaxel-incorporated nanoparticle-coated balloon in rabbit and porcine models.
Cardiovasc Revasc Med
; 19(4): 433-437, 2018 06.
Article
en En
| MEDLINE
| ID: mdl-29174499
ABSTRACT
BACKGROUND:
The main drawback of current available drug coated balloons (DCB) is that a certain percentage of the coated drug is lost in the bloodstream during its delivery to the target lesion. We integrated the nanoparticle-mediated drug delivery technology and polydimethylsiloxane (PDMS) as a new excipient to facilitate an efficient drug delivery and uptake by endothelial cells. The present study aimed to evaluate the efficacy of the new DCB. METHOD ANDRESULTS:
The novel DCB were coated with 5.6mg of paclitaxel-incorporated nanoparticles using PDMS. The efficacy of the new DCB was examined in rabbit iliac stent model (n=12) and in the swine in-stent restenosis model (n=8) by quantitative coronary angiography (QCA) and optical coherence tomography (OCT). At 28days follow-up in the swine in-stent restenosis model, the area stenosis was significantly lower in DCB group as compared with that of the control group in OCT analysis (0.31±0.05 vs 0.49±0.06, p=0.04) though there was no significant differences observed in the rabbit iliac stent model in QCA and OCT analysis.CONCLUSION:
The study results indicated that the paclitaxel-incorporated nanoparticle-coated balloon using PDMS has an inhibitory effect for the proliferation of smooth muscle cell in a swine coronary in-stent restenosis model.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Cateterismo Cardíaco
/
Fármacos Cardiovasculares
/
Paclitaxel
/
Materiales Biocompatibles Revestidos
/
Reestenosis Coronaria
/
Nanopartículas
/
Intervención Coronaria Percutánea
/
Catéteres Cardíacos
/
Arteria Ilíaca
Tipo de estudio:
Prognostic_studies
Idioma:
En
Revista:
Cardiovasc Revasc Med
Asunto de la revista:
ANGIOLOGIA
/
CARDIOLOGIA
Año:
2018
Tipo del documento:
Article
País de afiliación:
Japón